After finishing at $0.14 in the prior trading day, Novabay Pharmaceuticals Inc (AMEX: NBY) closed at $0.13, down -5.36%. In other words, the price has decreased by -$0.0073 from its previous closing price. On the day, 1991227 shares were traded.
Ratios:
Our goal is to gain a better understanding of NBY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on September 18, 2019, initiated with a Buy rating and assigned the stock a target price of $1.10.
On July 06, 2018, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $4.
Laidlaw reiterated its Buy rating for the stock on November 15, 2017, while the target price for the stock was revised from $10 to $8.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBY now has a Market Capitalization of 4.10M and an Enterprise Value of 5.60M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.27 while its Price-to-Book (P/B) ratio in mrq is 0.17. Its current Enterprise Value per Revenue stands at 0.38 whereas that against EBITDA is -0.85.
Stock Price History:
Over the past 52 weeks, NBY has reached a high of $1.95, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is 0.1500, while the 200-Day Moving Average is calculated to be 0.4083.
Shares Statistics:
The stock has traded on average 3.33M shares per day over the past 3-months and 1.97M shares per day over the last 10 days, according to various share statistics. A total of 30.10M shares are outstanding, with a floating share count of 29.36M. Insiders hold about 2.44% of the company’s shares, while institutions hold 3.95% stake in the company. Shares short for NBY as of Feb 29, 2024 were 271.72k with a Short Ratio of 0.08, compared to 576.56k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.16% and a Short% of Float of 4.16%.
Earnings Estimates
Its stock is currently analyzed by 1 different market analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.3, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.2 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$2.31 and -$2.31 for the fiscal current year, implying an average EPS of -$2.31. EPS for the following year is -$0.73, with 1 analysts recommending between -$0.73 and -$0.73.
Revenue Estimates
1 analysts predict $3.4M in revenue for the current quarter. It ranges from a high estimate of $3.4M to a low estimate of $3.4M. As of the current estimate, Novabay Pharmaceuticals Inc’s year-ago sales were $3.64M, an estimated decrease of -6.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $4M, an increase of 25.00% over than the figure of -$6.70% in the same quarter last year. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $4M.
Based on 1 analysts’ estimates, the company’s revenue will be $16M in the next fiscal year. The high estimate is $16M and the low estimate is $16M. The average revenue growth estimate for next year is up 11.10% from the average revenue estimate for this year.
